2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2342 Miv-cel (mivocabtagene autoleucel) CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrates evidence of broad immune reset in stiff person syndrome: Data from the pivotal, Phase 2 kysa-8 study

Marinos C Dalakas, MD, PhD, FAAN, Anastasia Zekeridou, MD2, Usama Gergis, MD, MBA3, Jonathan Gutman, MD4, Saad Kenderian, M.B., Ch.B.5, Mallory Lowe, MD6, Andrew McKeon, MD, PhD7, Sean J Pittock, MD, PhD8, Goran Rakocevic, MD9, Jessica J Yi, MD10, Justin Chou, PhD11, Xue Han, MS, MPH12, John Sun, PhD13, Shouvonik Sengupta, PhD14, Ryan Tooker, PhD15, Aditi Mehta, DO16, Dena Grayson, MD, PhD17, Naji Gehchan, MD, MBA18, Amanda L Piquet, MD19
1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Departments of Neurology and Laboratory Medicine and Pathology, and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, United States
3 Department of Oncology, Jefferson Health, Philadelphia, Pennsylvania, United States
4 Department of Oncology, University of Colorado Anschutz, Aurora, Colorado, United States
5 Division of Hematology, Department of Immunology, and Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States
6 Department of Neurology, University of Colorado Anschutz, Aurora, Colorado, United States
7 Departments of Neurology and Laboratory Medicine and Pathology, and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, United States
8 Departments of Neurology and Laboratory Medicine and Pathology, and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, United States
9 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
10 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
11 Kyverna Therapeutics, Inc., Emeryville, California, United States
12 Kyverna Therapeutics, Inc., Emeryville, California, United States
13 Kyverna Therapeutics, Inc., Emeryville, California, United States
14 Kyverna Therapeutics, Inc., Emeryville, California, United States
15 Kyverna Therapeutics, Inc., Emeryville, California, United States
16 Kyverna Therapeutics, Inc., Emeryville, California, United States
17 Kyverna Therapeutics, Inc., Emeryville, California, United States
18 Kyverna Therapeutics, Inc., Emeryville, California, United States
19 Department of Neurology, University of Colorado Anschutz, Aurora, Colorado, United States

Introduction: Stiff person syndrome (SPS) is a progressive, autoimmune neurologic disease characterized by muscle stiffness and painful spasms, leading to substantial disability. B cells are linked to SPS pathogenesis, supported by glutamic acid decarboxylase (GAD)-specific B-cell activity in the central nervous system, blood, and bone marrow (Dalakas. Nat Rev Neurol. 2024). 

Miv-cel is a unique, fully human, autologous CD19 CAR T-cell therapy with CD28 costimulation designed for potency and tolerability. The phase 2 KYSA-8 (NCT06588491) study of miv-cel has delivered the first pivotal data for CAR T in SPS (Piquet. AAN 2026. Abstract LS2.008). The primary endpoint was met with significant (P=.0003) improvement from baseline to week 16 in the timed 25-foot walk, and significant (P<.0001) improvements in all secondary endpoints (modified Rankin scale, stiffness index, heightened sensitivity scale, and Hauser ambulation index). Miv-cel showed a consistent, well-tolerated safety profile with no high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. As of last available follow-up (median 6.5 months [range, 4.4-12.2]), all patients remained free of SPS immunomodulatory therapies. Here, we profiled cellular and molecular changes following miv-cel treatment in KYSA-8. 

Methods: Adults 18–75 years old with SPS and inadequate immunomodulatory/immunosuppressive therapy response received low-dose lymphodepletion (fludarabine 30 mg/m2/day, cyclophosphamide 300 mg/m2/day; 3 days), followed by a single miv-cel infusion (1×108 CAR T cells). Pre-specified exploratory endpoints included ddPCR quantification of CAR T cells, immunoassay evaluation of systemic autoantibody and cytokine levels, and flow cytometric immunophenotyping of peripheral (PBMC) T- and B-cell subsets at week 16. 

Results: In 26 patients enrolled and treated, miv-cel demonstrated rapid in vivo expansion; CAR-positive T cells peaked by day 14 (range, 7-21) at a median of 108.4 cells/μL blood (range, 28.0–1059.4). Concurrent B-cell depletion was observed by day 5. B-cell reconstitution (cell levels above the lower limit of quantification) was seen in 54% (14/26) of patients by week 16, and efficacy was maintained with reconstitution. Reciprocal kinetics demonstrated an inverse relationship between CAR T-cell detection and B-cell reconstitution.  

GAD65-IgG titers were reduced in 95% (19/20) of patients with ≥20 nM GAD65-IgG at baseline, with significant (P<.0001) median 56% reduction at week 16. GAD65-IgG also significantly decreased (P<.0001) from baseline at week 16 regardless of whether patients had B-cell reconstitution.  

Circulating levels of pro- and anti-inflammatory cytokines (29 in total) were assessed from baseline to day 56. Following miv-cel infusion, 13 cytokines significantly increased (log2 fold change >2), with the highest peaks relative to baseline seen in IFN-γ, IL-6, and IL-10. By day 56, 92% (12/13) of cytokines returned to near-baseline levels. Only BAFF, a B-cell trophic factor known to increase after B-cell depleting therapies, remained significantly upregulated at day 56. Overall, transient cytokine increases demonstrated robust immune activation by miv-cel.  

B-cell compartment remodeling and T-cell modulation were observed following miv-cel treatment, supportive of immune reset. In 10 patients with B-cell reconstitution and available data, naïve B cells significantly increased (P=.0098) alongside a trend toward increased transitional B cells. Concurrent decreases in memory B-cell compartments included significantly decreased class-switched (P=.0039) and double-negative (P=.0273) B cells, with trends of decreased non-class switched and activated memory B cells. From baseline, significantly increased Tregs (P<.0001) and decreased Tfh (P=.0006) and Th2 (P<.0001) cells were seen at week 16 across 23 patients with available data. Th1 and Th17 cells were unchanged at week 16.  

Conclusions: Miv-cel treatment resulted in B-cell depletion, significant reduction of autoantibody levels, and immunologic changes suggestive of broad immune reset, including B- and T-cell compartment remodeling in patients with SPS. These coordinated changes suggest re-establishment of immune homeostasis beyond transient B-cell depletion, and provide mechanistic insights supporting the potential for miv-cel to elicit immunotherapy-free durable remissions in SPS. Updated 1-year follow-up data will be presented. 

Marinos C Dalakas, MD, PhD, FAAN: Kyverna Therapeutics, Inc. - Consultancy (Includes expert testimony); Grifols, S.A. - Consultancy (Includes expert testimony); Octapharma AG - Consultancy (Includes expert testimony); Argenx SE - Membership on a Board/Advisory Committee